Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Tumor-Treating Fields Continues to Garner Interest in Glioblastoma

October 26th 2021

Concurrent use of tumor-treating fields, radiation therapy, and temozolomide is under study as a potential treatment for patients with newly diagnosed, stage IV glioblastoma.

Scope of Treatment Sequencing Grows in Genitourinary Malignancies

October 26th 2021

Jonathan A. Chatzkel, MD, discusses updates in first-line treatment options for metastatic urothelial cancer, as well as recommended treatments for patients with previously treated, locally advanced or metastatic urothelial cancer, and also newly diagnosed metastatic renal cell carcinoma.

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

October 21st 2021

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

IGHV Mutation Status Now Included in clonoSEQ Diagnostic Assay in CLL

October 20th 2021

An upgraded model of the clonoSEQ® B-cell Clonality diagnostic tool has been released, which will now include IGHV mutation status for patients with chronic lymphocytic leukemia.

Chemoimmunotherapy Combos, Adjuvant Approaches and Bispecifics Are Among Exciting Advances in Lung Cancer

October 19th 2021

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

ADCs, Checkpoint Inhibitors Generate Discussion at ESMO 2021 in Lung Cancer

October 15th 2021

Alexander I. Spira, MD, PhD, FACP, discusses impactful data from the 2021 ESMO Congress in lung cancer.

Older Age Is Associated With Worse Survival Outcomes in MCL

October 15th 2021

Patients with newly diagnosed mantle cell lymphoma who were 65 years of age or older had worse progression-free survival and overall survival at 1 and 2 years compared with patients under the age of 65 years.

Nurse Practitioners Are a Touchstone in Lung Cancer Management

October 14th 2021

Communication and education of a patient with lung cancer and their family is only part of a nurse practitioner’s responsibility. Moreover, they often represent the primary point of contact for a patient when it comes to their diagnostic workup, treatment follow-up, and symptom management.

PROMIS Scores Provide Insight Into PROs With Radiation Therapy in Soft Tissue Sarcoma

October 14th 2021

Patient Reported Outcomes Measurement Information System scoring indicated that preoperative and postoperative radiation therapy was associated with worse anxiety and physical function in patients with soft tissue sarcoma who had resulting wound complications compared with those who did not.

Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC

October 12th 2021

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee

October 11th 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers

October 11th 2021

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.

SERDs, ADCs Broaden Research Avenues Throughout Breast Cancer

October 8th 2021

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

Immunotherapy, Second-Generation AR Antagonists Provide Expansive Utility Throughout Prostate Cancer

October 7th 2021

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

MSH3 IHC and Tetranucleotide MSI Analysis Should Not Be Routine in CRC

October 7th 2021

MSH3 immunohistochemistry and tetranucleotide analysis failed to demonstrate concordance in identifying microsatellite instability in a cohort of colorectal cancer cases at selected tetranucleotide repeats, suggesting that the dual assessment strategy is not ready for routine use in diagnostic workup.

Monthly Dosing of Consolidation Durvalumab Is Key in Stage III NSCLC

October 6th 2021

Sandip P. Patel, MD, discussed the real-world application of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.

Key Advances Showcase the Potential of Precision Medicine in NSCLC

October 5th 2021

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

Treatment Should Not Be Dependent on Age in Soft Tissue Sarcoma

October 4th 2021

Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.

Concurrent Immunotherapy and Chemoradiation Under Study in Stage III NSCLC

October 4th 2021

Martin F. Dietrich, MD, PhD, discusses the significance of the PACIFIC trial on clinical practice and research efforts in stage III non–small cell lung cancer, expectations for ongoing clinical trials, and the emergence of targeted therapy in the adjuvant setting

Rovalpituzumab Tesirine Falls Flat in Small Cell Lung Cancer

October 1st 2021

Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.